| Title | In situ Delivery of Therapeutic Proteins by Recombinant Lactococcus lactis |
|---|---|
| Author | Lothar Steidler * and Sabine Neirynck |
| Address | University College Cork, Western Road, Cork, Ireland (Received May 2, 2003) |
| Bibliography | Journal of Microbiology, 41(2),63-72, 2003, |
| DOI | |
| Key Words | Lactococcus lactis, inflam-matory bowel disease, thyA, interleukin-10 |
| Abstract | Chronic inflammatory bowel disease (IBD) such as Crohn’s disease or ulcerative colitis, affects around 2 in every 1000 individuals in western countries and its incidence, particularly amongst children, is increasing. IBD shows extreme morbidity with impact on all aspects of quality of life. If left untreated, IBD can lead to death. Conventional treatment of IBD involves powerful immunosuppressive chemotherapies and surgical intervention. Long-term anti-inflammatory medication is required and so patients are often subject to a spectrum of unpleasant side effects. Interleukin-10 (IL-10) is a cytokine that acts to suppress inflammation. When however administered by injection, the high levels of IL-10 that are distributed throughout the body also lead to side effects. Lactococcus lactis can be genetically engineered to secrete biologically active cytokines. When applied to the mucosa, these L. lactis can actively deliver such cytokines. By use of this principle we developed a new therapeutic approach for IBD. Administration of L. lactis that secretes murine IL-10 cures and prevents IBD in mice. The use of the engineered L. lactis gets around the problem of delivering IL-10, allowing dramatic reduction of the effective dose. A sincere concern exists about the possible dangers of uncontrolled, deliberate release of genetically modified microorganisms, such as could occur following application in healthcare. We engaged in the establishment of adequate means for biological growth control of engineered L. lactis by targeted |
| Download PDF | 412-14.pdf |